Gefarnate
Appearance
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.000.111 |
Chemical and physical data | |
Formula | C27H44O2 |
Molar mass | 400.647 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Gefarnate is a drug used for the treatment of gastric ulcers.[1]
It also has been proposed for use in the treatment of dry eye syndrome.[2][3]
References
[edit]- ^ Ohta Y, Kobayashi T, Imai Y, Inui K, Yoshino J, Nakazawa S (August 2005). "Effect of gefarnate on acute gastric mucosal lesion progression in rats treated with compound 48/80, a mast cell degranulator, in comparison with that of teprenone". Biol. Pharm. Bull. 28 (8): 1424–30. doi:10.1248/bpb.28.1424. PMID 16079487.
- ^ Peral A, Domínguez-Godínez CO, Carracedo G, Pintor J (April 2008). "Therapeutic targets in dry eye syndrome". Drug News Perspect. 21 (3): 166–76. doi:10.1358/dnp.2008.21.3.1203413. PMID 18560615.
- ^ Gipson IK, Hori Y, Argüeso P (April 2004). "Character of ocular surface mucins and their alteration in dry eye disease". Ocul Surf. 2 (2): 131–48. doi:10.1016/s1542-0124(12)70149-0. PMID 17216084.[permanent dead link ]